Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with
significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an …

Abstract Treatment of severe aplastic anemia has improved significantly over the past 4
decades. This review will summarize the key areas of progress in the use of allogeneic …

Background Bone marrow has been shown to be superior to peripheral blood, as a stem cell
source, in young patients (< 20 years of age) with acquired aplastic anemia undergoing a …

Opinion statement Acquired aplastic anemia (AA) is a rare, life-threatening bone marrow
failure (BMF) disorder that affects patients of all ages and is caused by lymphocyte …

Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body
irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective …

Background Transplantation from an HLA-matched sibling is the treatment of choice for
young patients with acquired severe aplastic anemia. For older patients, the acceptable …

Abstract Treatment options for newly diagnosed aplastic anemia (AA) patient includes
upfront allogeneic hematopoietic stem cell transplant (HSCT) or immunosuppressive …

We evaluated a novel alemtuzumab-based conditioning regimen in HSCT for acquired
severe aplastic anemia (SAA). In a multicenter retrospective study, 50 patients received …

Advances in hematopoietic stem cell transplantation (HSCT) and immunosuppressive
therapy (IST) have improved survival in severe aplastic anemia (SAA) from 10%-20% in the …

The conversion of somatic cells into pluripotent cells is transforming the way diseases are
researched and treated. Induced pluripotent stem (iPS) cells' promise may soon be realized …